Kovitz Investment Group Partners
TSHA icon

Kovitz Investment Group Partners’s Taysha Gene Therapies TSHA Stock Holding History

Kovitz Investment Group Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-298,667
Closed -$977K – 1249
2025
Q3 		$977K Hold
298,667
– – ﹤0.01% 849
2025
Q2 		$690K Buy
298,667
+5,889
+2% +$12.8K ﹤0.01% 881
2025
Q1 		$407K Hold
292,778
– – ﹤0.01% 968
2024
Q4 		$507K Hold
292,778
– – ﹤0.01% 885
2024
Q3 		$588K Hold
292,778
– – ﹤0.01% 727
2024
Q2 		$656K Buy
292,778
+15,000
+5% +$43.6K 0.01% 616
2024
Q1 		$797K Hold
277,778
– – 0.01% 443
2023
Q4 		$492K Buy
277,778
+252,778
+1,011% +$504K 0.01% 331
2023
Q3 		$79K Buy
25,000
+10,000
+67% +$18.7K ﹤0.01% 392
2023
Q2 		$9.91K Hold
15,000
– – ﹤0.01% 406
2023
Q1 		$12K Hold
15,000
– – ﹤0.01% 416
2022
Q4 		$34K Buy
+15,000
New +$30.4K ﹤0.01% 389
2020
Q4 		– Sell
-10,000
Closed -$224K – 427
2020
Q3 		$224K Buy
+10,000
New +$235K 0.01% 379

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kovitz Investment Group Partners's TSHA Position: Q4 2025 in Review

Kovitz Investment Group Partners sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 298,667 shares — an estimated $977K sold.

Kovitz Investment Group Partners first reported a position in TSHA in Q3 2020 and held it in 13 quarters. The position peaked at $977K in Q3 2025. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Kovitz Investment Group Partners reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 298,667 Taysha Gene Therapies shares in Q4 2025, an estimated $977K.
  • Kovitz Investment Group Partners first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 13 quarters.
  • Kovitz Investment Group Partners's Taysha Gene Therapies position peaked at $977K in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Kovitz Investment Group Partners's 13F filing for Q4 2025, filed 20 Feb 2026.